cbdMD, Inc. (YCBD)
0.5299
+0.04
(+8.59%)
USD |
NYAM |
Aug 25, 16:00
0.5299
0.00 (0.00%)
After-Hours: 17:33
cbdMD Gross Profit Margin (Quarterly) : 50.03% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 50.03% |
| March 31, 2026 | 53.29% |
| December 31, 2025 | 54.93% |
| September 30, 2025 | 53.28% |
| June 30, 2025 | 55.37% |
| March 31, 2025 | 56.29% |
| December 31, 2024 | 60.67% |
| September 30, 2024 | 52.19% |
| June 30, 2024 | 60.22% |
| March 31, 2024 | 52.33% |
| December 31, 2023 | 60.90% |
| September 30, 2023 | 47.99% |
| June 30, 2023 | 56.70% |
| March 31, 2023 | 58.27% |
| December 31, 2022 | 52.43% |
| September 30, 2022 | 57.42% |
| June 30, 2022 | 63.97% |
| March 31, 2022 | 58.75% |
| Date | Value |
|---|---|
| December 31, 2021 | 49.91% |
| September 30, 2021 | 55.60% |
| June 30, 2021 | 65.74% |
| March 31, 2021 | 67.08% |
| December 31, 2020 | 70.29% |
| September 30, 2020 | 54.41% |
| June 30, 2020 | 64.76% |
| March 31, 2020 | 70.93% |
| December 31, 2019 | 63.54% |
| September 30, 2019 | 59.10% |
| June 30, 2019 | 63.41% |
| March 31, 2019 | 66.03% |
| December 31, 2018 | 64.46% |
| September 30, 2018 | 43.94% |
| June 30, 2018 | 65.40% |
| March 31, 2018 | 83.00% |
| December 31, 2017 | 66.82% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Tilray Brands, Inc. | 29.93% |
| Organogenesis Holdings, Inc. | 30.84% |
| Guardian Pharmacy Services, Inc. | 22.75% |
| Nektar Therapeutics | 98.46% |
| Elite Pharmaceuticals, Inc. | 40.61% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -36.25% |
| Return on Assets | -25.12% |
| Return on Invested Capital | -32.23% |
| Profit Margin (Quarterly) | -20.30% |
| Operating Margin (Quarterly) | -20.36% |
| Return on Net Operating Assets | -33.45% |